TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06649604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Anesthesia Device
Description: The intervention arm of this study is distinguished by way of the use of the Vibration Anesthesia Device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation
Description: Laser treatment for diabetic retinopathy done in a standard fashion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation
Description: Laser treatment for diabetic retinopathy done in a standard fashion
Study: NCT06144606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecartus
Description: Tecartus is a CD19 directed CAR T-cell therapy that utilizes CD28 costimulatory and CD3 zeta stimulatory domains. Tecartus is manufactured from purified autologous T-cells via retroviral transduction with a median time to product release of 13 days.
Study: NCT05928026

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Support
Description: A debit card will be loaded with $500 and can be used like a typical debit card.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Support
Description: A debit card will be loaded with $500 and can be used like a typical debit card.
Study: NCT06422884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENV-101
Description: oral tablet, dosed once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENV-101
Description: oral tablet, dosed once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENV-101
Description: oral tablet, dosed once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, dosed once a day
Study: NCT05619510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIME Intervention
Description: Participants who are randomized to the intervention will participate in five virtual or in person visits with a nurse where the nurse uses self regulation theory as a guide to help them set their own goals surrounding pain and depression and use tailored strategies to address these goals. The second component will include six virtual Acceptance Commitment Therapy (ACT) sessions, led by a clinical psychologist. There will be 3-5 other research participants in the sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PRIME Intervention
Description: Participants who are randomized to the intervention will participate in five virtual or in person visits with a nurse where the nurse uses self regulation theory as a guide to help them set their own goals surrounding pain and depression and use tailored strategies to address these goals. The second component will include six virtual Acceptance Commitment Therapy (ACT) sessions, led by a clinical psychologist. There will be 3-5 other research participants in the sessions.
Study: NCT06487559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Intravenous infusion
Study: NCT06346795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-filling flowable dental composite
Description: Class II restorations will be performed with G-aenial Universal Injectable, Grandio Flow, and Clearfil Majesty Flow high-filling flowable composites.
Study: NCT05953038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide Tartrate
Description: D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)
Study: NCT05035654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYR-220 Design 1 (Part 1 only)
Description: LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
Study: NCT06346795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-filling flowable dental composite
Description: Class II restorations will be performed with G-aenial Universal Injectable, Grandio Flow, and Clearfil Majesty Flow high-filling flowable composites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-filling flowable dental composite
Description: Class II restorations will be performed with G-aenial Universal Injectable, Grandio Flow, and Clearfil Majesty Flow high-filling flowable composites.
Study: NCT06487559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Intravenous infusion
Study: NCT05795855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADEPT
Description: Prenatal providers will participate in trainings that will lay the foundation for an effective vaccination recommendation. After the completion of training, prenatal care providers will begin making recommendations promoting the importance of maternal and childhood vaccinations to pregnant individuals, as part of routine prenatal care. The core component of ADEPT is prenatal provider training to enable a vaccination recommendation, encouraging pregnant individuals to receive vaccines during pregnancy and for their child after birth. Pregnant individuals who remain vaccine hesitant despite the provider recommendation, will be eligible to receive the adaptive components of ADEPT in the form of evidence-based educational materials on vaccinations and phone consultations with a vaccine navigator to discuss residual concerns.
Study: NCT06521463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN FLX Pro LAAC Device
Description: WATCHMAN FLX Pro LAAC Device Implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WATCHMAN FLX Pro LAAC Device
Description: WATCHMAN FLX Pro LAAC Device Implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN FLX Pro LAAC Device
Description: WATCHMAN FLX Pro LAAC Device Implantation
Study: NCT06067113

Intervention type: PROCEDURE
Intervention: Supraaortic and transcranial duplex
Description: Ecographic evaluation of supraaortic and transcranial arteries, including presence of plaques, flow velocities and pulsatility index

Intervention type: PROCEDURE
Intervention: Supraaortic and transcranial duplex
Description: Ecographic evaluation of supraaortic and transcranial arteries, including presence of plaques, flow velocities and pulsatility index
Study: NCT04943211

Intervention type: DRUG
Group type: OTHER
Intervention: fluorodeoxyglucose (18F-FDG)
Description: max 6 MGBq/kg, no more than 100
Study: NCT05779852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-hypnosis and dressing
Description: self-hypnosis during dressing

Intervention type: OTHER
Group type: OTHER
Intervention: dressing
Description: dressing without self-hypnosis
Study: NCT06270992

Intervention type: DIAGNOSTIC_TEST
Intervention: NCCN (National Comprehensive Cancer Network) diagnosis
Description: For diagnostic evaluation, the necessary procedures from the standard protocols consisting of anamnesis, physical examination, laboratory tests, radiological imaging methods, and tissue biopsy will be followed. Computerized Tomography (CT) and Positron Emission Tomography-Computed Tomography (PET-CT) will be used as imaging methods, while fiberoptic bronchoscopy and video-assisted mediastinoscopy will be applied for tissue diagnosis and staging.

Intervention type: DIAGNOSTIC_TEST
Intervention: NCCN (National Comprehensive Cancer Network) diagnosis
Description: For diagnostic evaluation, the necessary procedures from the standard protocols consisting of anamnesis, physical examination, laboratory tests, radiological imaging methods, and tissue biopsy will be followed. Computerized Tomography (CT) and Positron Emission Tomography-Computed Tomography (PET-CT) will be used as imaging methods, while fiberoptic bronchoscopy and video-assisted mediastinoscopy will be applied for tissue diagnosis and staging.
Study: NCT05035654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYR-220 Design 2 (Part 1 and Part 2)
Description: LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
Study: NCT06279013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Receive TIPC

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Receive handbook

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring
Description: Receive IVR symptom monitoring

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: Receive IVR symptom monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06001307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program STARS (Supporting Trans Affirmation, relationships, and Sex)
Description: See description to the left.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation and Stress Reduction
Description: See description to the left.
Study: NCT06217146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Cannabis
Description: MediCane's medical cannabis oil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: Placebo Oil
Study: NCT05035654

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bilateral sham procedure control (Part 2)
Description: Bilateral sham procedure control
Study: NCT04811079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 419 nm Spectacle Filter
Description: TEST
Study: NCT06717269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948 capsule
Description: NX-5948 in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948 capsule
Description: NX-5948 in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948 tablet
Description: NX-5948 in tablet form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948 tablet
Description: NX-5948 in tablet form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole capsule, once daily
Study: NCT06731023

Intervention type: DRUG
Intervention: Bismuth
Description: Bismuth 0.6g bid

Intervention type: DRUG
Intervention: Bismuth
Description: Bismuth 0.6g bid

Intervention type: DRUG
Intervention: Bismuth
Description: Bismuth 0.6g bid
Study: NCT05914779

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No use of antibiotics
Description: Subjects will be randomized into antibiotics and no antibiotics groups based on inclusion and exclusion criteria
Study: NCT06731023

Intervention type: DRUG
Intervention: Vonoprazan
Description: vonoprazan 20mg bid

Intervention type: DRUG
Intervention: Vonoprazan
Description: vonoprazan 20mg bid

Intervention type: DRUG
Intervention: Vonoprazan
Description: vonoprazan 20mg bid

Intervention type: DRUG
Intervention: Amoxicillin
Description: Amoxicillin 1g bid

Intervention type: DRUG
Intervention: Amoxicillin
Description: Amoxicillin 1g bid

Intervention type: DRUG
Intervention: Amoxicillin
Description: Amoxicillin 1g bid

Intervention type: DRUG
Intervention: Rifabutin
Description: Rifabutin 0.15g bid

Intervention type: DRUG
Intervention: Rifabutin
Description: Rifabutin 0.15g bid

Intervention type: DRUG
Intervention: Rifabutin
Description: Rifabutin 0.15g bid

Intervention type: DRUG
Intervention: Metronidazole
Description: Metronidazole 400mg qid

Intervention type: DRUG
Intervention: Other antibiotics
Description: The selection of other antibiotics is based on the results of drug susceptibility testing.
Study: NCT06732960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efsubaglutide Alfa
Description: Efsubaglutide Alfa subcutaneous injection under 1mg, 3mg, 5mg, 7.5mg, 10mg, 15mg or 20mg dose weekly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efsubaglutide Alfa
Description: Efsubaglutide Alfa subcutaneous injection under 1mg, 3mg, 5mg, 7.5mg, 10mg, 15mg or 20mg dose weekly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efsubaglutide Alfa
Description: Efsubaglutide Alfa subcutaneous injection under 1mg, 3mg, 5mg, 7.5mg, 10mg, 15mg or 20mg dose weekly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efsubaglutide Alfa
Description: Efsubaglutide Alfa subcutaneous injection under 1mg, 3mg, 5mg, 7.5mg, 10mg, 15mg or 20mg dose weekly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efsubaglutide Alfa
Description: Efsubaglutide Alfa subcutaneous injection under 1mg, 3mg, 5mg, 7.5mg, 10mg, 15mg or 20mg dose weekly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaneous injection weekly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaneous injection weekly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaneous injection weekly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaneous injection weekly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaneous injection weekly
Study: NCT06737367

Intervention type: OTHER
Intervention: CT radiomic analysis
Description: Radiomic features of tumor and peritumor tissue

Intervention type: OTHER
Intervention: CT radiomic analysis
Description: Radiomic features of tumor and peritumor tissue
Study: NCT06741410

Intervention type: DRUG
Intervention: Ephedrine
Description: Intravenous boluses of ephedrine

Intervention type: DRUG
Intervention: Phenylephrine
Description: Intravenous continuous infusion of phenylephrine
Study: NCT06742996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered orally
Study: NCT05970211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audeo Lumity Receiver in Canal Hearing Aid
Description: bilateral receiver in canal hearing aids provided as part of a best practices hearing loss intervention including devices, hearing centered counseling, and self management skills training for hearing loss
Study: NCT06742996

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zanubrutinib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06742606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group 1 of patients will receive Adalimumab while Group 1 will receive ustekinumab
Description: All the patients will be treated according to guidelines of ECCO/ESPGHAN and will be followed up regularly for 12 months by assessment~• response to treatment Frequency of relapses,~Regular assessment will be:~Clinically every 2 to 4 weeks at gastroenterology outpatient clinic by using activity scoring systems:~pediatric Ulcerative Colitis Activity Index pediatric Chron's Disease Activity Index~Laboratory follow up will done at weeks 12,24,36,48 of starting or changing to other biological by doing inflammatory markers( CBC, ESR, CRP, albumin. At the end of study(week 48) each patient will be reassessed by:~Disease activity:~Laboratory Endoscopy will be repeated at week 48 of starting or changing to other biological to assess effect of biologicals on reach mucosal healing.
Study: NCT06742125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Description: Drug-coated balloon treatment of target lesions in patients with premature STEMI undergoing percutaneous coronary intervention.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent (DES)
Description: Drug-eluting stent treatment of target lesions in patients with premature STEMI undergoing percutaneous coronary intervention.
Study: NCT06742892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 1
Description: Dose 1; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 2
Description: Dose 2; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 3
Description: Dose 3; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study: NCT06743022

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chest CT
Description: Repeated chest CT for automated ILD quantification
Study: NCT06743451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health workers training on GMP guideline
Description: One day training will be conducted to health workers on updated GMP guideline for the health workers primarily engaged in Growth monitoring and promotion of the children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Female community health volunteers' mobilization for inviting mothers and caretakers
Description: Female community health volunteers will be mobilized for inviting mothers and caretakers for two consecutive months for enhancing GMP practices in the municipality
Study: NCT06743438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Amibufenamide（TMF）
Description: Once-daily oral dose of 25 mg TMF were maintained in all participants
Study: NCT06741956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weapom Lifestyle Intervention to measure bone impacts using a Fitbit Versa wearable device and the Weapom App.
Description: A. Program to increase physical activity and impacts For the intervention, a biosensor -wearable device- (Fitbit Versa) will be used. The device is linked to an App (Weapom) that will allow users to quantify the number of steps (including the rate of steps per minute), the impacts and their intensity. Users will be given feedback from the application on the level of achievement of the objectives proposed in the impact program (EV). It will be proposed to achieve 50 vertical and multidirectional jumps per day (milestone 1. The number of jumps\> 3.9 G per day will be recorded 28, divided between 3-5 sets of 10-20 repetitions with a minimum 1-2 minute rest between sets. A frequency between 4-7 days per week will be used. In the same way, it will be recommended to reach 10,000 steps per day (milestone 2. The number of daily steps will be recorded) and, as far as possible, at a rapid pace (milestone 3. The number of daily minutes walking at a pace over 110 steps/minute will be r
Study: NCT06741488

Intervention type: OTHER
Intervention: no intervention
Description: Exercise Adaptation Rating Scale
Study: NCT06743204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Reported Risk Screening for PrEP and Diagnostic STI testing
Description: The intervention arm will include: 1) Standard-of-care STI symptom screening: The investigators will ask participants if any STI symptoms 2) PrEP screening (if HIV- only): PrEP eligibility screening will be done using the standard-care Ministry Health self-reported risk screening (SRST) tool for PrEP 3) STI laboratory diagnostic testing: Regardless of HIV serostatus, vaginal swabs will be collected to test for chlamydia, gonorrhea, trichomonas, and human papilloma virus. Syphilis testing will be performed using blood samples participants provided in the Rakai Community Cohort Study. Participants who test positive for a curable sexually transmitted infection (chlamydia, gonorrhea, trichomonas, or syphilis) OR who screen eligible for PrEP using the Ministry of Health SRST AND are HIV- will be referred for same-day PrEP initiation. Participants who have symptoms indicative of STIs or who test positive for an STI will be provided with free treatment, as will the partner(s).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-reported risk screening for PrEP and syndromic management for STIs
Description: This active comparator (control) arm will receive the following: 1) Standard-of-care STI symptom screening: Regardless of HIV serostatus, participants will be asked if any STI symptoms 2) Syphilis testing for pregnant participants: Regardless of HIV serostatus, syphilis testing will be performed using blood samples provided in the Rakai Community Cohort Study. 3) PrEP screening (if HIV- only): Participants will be screened for PrEP eligibility using the standard-care Ministry Health self-reported risk screening (SRST) tool for PrEP. Participants who screen eligible for PrEP using the Ministry of Health SRST OR pregnant participant's who test positive for syphilis AND are HIV- will be referred for same-day PrEP initiation. Participants who have symptoms indicative of STIs or who test positive for syphilis will be provided with free treatment, as will the partner(s).
Study: NCT06743321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-to-speech Voice-Cloning Care (SVCC)
Description: After patients in the intervention group were transferred to the ICU, the SVCC intervention was initiated. It is administered three times daily: in the morning, at noon, and in the evening. The SVCC intervention includes three types of activities: awakening, reassurance, and preparatory exercises for the removal of the endotracheal tube (ETT). Before each intervention is carried out, the clinical status of the participants must be assessed to determine whether they are suitable for SVCC and to decide on the specific content of the intervention. Once the removal of the ETT is implemented, the SVCC intervention will no longer be carried out.
Study: NCT03984565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: High-CBD, low-THC sublingual product formulated in palm oil
Study: NCT06548243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Act with Nature Programme
Description: The participants in the intervention group are offered a 12-week nature-based programme, which includes independent exercises and information on an online learning environment, as well as online or in-person group meetings.
Study: NCT04811079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 419 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 419 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 419 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 419 nm Spectacle Filter
Description: TEST
Study: NCT05914779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: with antibiotics treatment
Description: with antibiotics treatment
Study: NCT06481358

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence
Description: AI extract intestinal region and reconstruct into 3D image.